Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

NCT04454437 | Active Not Recruiting Phase 2 DMC

• 2 other identifiers: EVER-132-001CTR20200914
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 17

Brief Summary

The goal of this study is to learn more about the effectiveness of the study drug, sacituzumab govitecan-hziy, in Chinese participants with metastatic triple-negative breast cancer (mTNBC) who received at least 2 systemic chemotherapy regimens.

Conditions

Metastatic Triple-negative Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Independent Review Committee (IRC)

  ORR is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR).

  Up to 3 years

Secondary Outcomes (8)

• Duration of Response (DOR) by IRC

  Up to 3 years

• Clinical Benefit Rate (CBR)

  Up to 3 years

• Progression-free Survival (PFS)

  Up to 3 years

• Overall survival (OS)

  Up to 3 years

• Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

  First dose date up to 3 years plus 30 days

Study Arms (1)

Sacituzumab Govitecan-hziy

EXPERIMENTAL

Participants will receive sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 of a 21-day cycle. Participants will continue treatment until disease progression or intolerable toxicity or consent withdrawal for any reason.

Drug: Sacituzumab Govitecan-hziy

Interventions

Sacituzumab Govitecan-hziy DRUG

Administered intravenously

Also known as: IMMU-132, Trodelvy™, GS-0132

Sacituzumab Govitecan-hziy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female Chinese, 18 years of age or older providing written informed consent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Histologically or cytologically confirmed Triple-negative Breast Cancer (TNBC).
• Refractory to or relapsed after at least 2 prior standard of care chemotherapy regimens for unresectable, locally advanced or metastatic breast cancer.
• Measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.
• Availability of archival tumor tissue or newly acquired biopsy (FFPE block or a minimum of number 10 unstaining tumor slides, recommended from recurrent or metastatic sites).
• For individuals with a documented germ-line BRCA1/BRCA2 mutation who received an approved PARP inhibitor, the PARP inhibitor can be used to meet the criteria for one of 2 prior standard of care chemotherapies.
• All individuals must have been previously treated with a taxane regardless of disease stage (adjuvant, neoadjuvant or advanced) when it was given. Individuals who have contraindications or are intolerant to taxanes are eligible provided that they received at least 1 cycle of a taxane and showed contraindications or intolerance during or at the end of that cycle.
• Adequate bone marrow, hepatic and renal function, defined as:
• hemoglobin \> 9 g/dL, absolute neutrophil count \> 1,500 per mm\^3, platelets \> 100,000 per mm\^3.
• creatinine clearance of \> 60 ml/min calculated using Cockcroft-Gault equation.
• bilirubin ≤ 1.5 Upper Limit of Normal (ULN), aspartate amino transferase and alanine amino transferase ≤ 2.5 × ULN or ≤ 5 × ULN if known liver metastases and serum albumin ≥ 3 g/dL.
• Recovered from all prior treatment-related toxicities to Grade 1 or less by National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0) (except alopecia or peripheral neuropathy that may be Grade 2 or less).
• Individuals must have completed all prior cancer treatments at least 2 weeks prior to the first dose including chemotherapy (includes also endocrine treatment), radiotherapy and major surgery. Prior antibody treatment for cancer must have been completed at least 3 weeks prior to the first dose.
• Individuals must have at least a 3-month life expectancy.

You may not qualify if:

• Previous treatment with topoisomerase 1 inhibitors as a free form or as other formulations.
• Individuals with a history of or current central nervous system (CNS) metastases. A scan to confirm the absence of brain metastases is not required. Individuals with unknown CNS metastatic status and any clinical signs indicative of CNS metastases are eligible if CNS metastases are excluded using CT and/or MRI scans.
• Individuals with Gilbert's disease.
• Individuals with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while individuals with other prior malignancies must have had at least a 3-year disease-free interval.
• Individuals known to be human immunodeficiency virus positive.
• Individuals with active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. In individuals with a history of HBV, hepatitis B core antibody (HBcAb) testing is required and if positive, then HBV DNA testing will be performed and if positive the individual will be excluded.
• Known history of unstable angina, myocardial infarction (MI), or chronic heart failure present within 6 months of first dose or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy or left ventricular ejection fraction \< 50%.
• Known history of clinically significant active chronic obstructive pulmonary disease, or other moderate-to-severe chronic respiratory illness present within 6 months of the first dose.
• Infection requiring systematic antibiotic use within 1 week of the first dose.
• Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal (GI) perforation.
• High dose systemic corticosteroids within 2 weeks prior to the first dose (however, low dose corticosteroids ≤ 10 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks).
• Scheduled surgery during the study, other than minor surgery which would not delay study treatment.
• Individuals who have received a live vaccine within 30 days of first dose.
• Rapid deterioration during Screening prior to the first dose, eg, significant change in performance status, unstable pain symptoms requiring modifications in analgesic management.
• Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

Sponsors & Collaborators

• Gilead Sciences: lead

Study Sites (17)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

Location

Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, China

Location

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, Zhejiang, China

Location

Chinese PLA General Hospital

Beijing, 100853, China

Location

The First Hospital of Jilin University

Changchun, 130021, China

Location

Hunan Cancer Hospital

Changsha, 410013, China

Location

West China Hospital, Sichuan University

Chengdu, China

Location

Chongqing University Cancer Hospital

Chongqing, 404100, China

Location

Sun Yat-sen University, Cancer Center

Guangzhou, 510000, China

Location

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, 510120, China

Location

Zhejiang Cancer Hospital

Hangzhou, 310022, China

Location

Anhui Provincial Hospital

Hefei, 230001, China

Location

The First Affiliated Hospital of Anhui Medical University

Hefei, 230022, China

Location

The First Hospital of China Medical University

Shenyang, 110001, China

Location

Tianjin Medical University Cancer Institute & Hospital

Tianjin, 300060, China

Location

Hubei Cancer Hospital

Wuhan, 430000, China

Location

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, 710061, China

Location

Related Publications (1)

• Xu B, Ma F, Wang T, Wang S, Tong Z, Li W, Wu X, Wang X, Sun T, Pan Y, Yao H, Wang X, Luo T, Yang J, Zeng X, Zhao W, Cong XJ, Chen J. A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. Int J Cancer. 2023 May 15;152(10):2134-2144. doi: 10.1002/ijc.34424. Epub 2023 Jan 30.

  PMID: 36621000 DERIVED

Related Links

• Gilead Clinical Trials Website

MeSH Terms

Conditions

Triple Negative Breast Neoplasms

Interventions

sacituzumab govitecan

Condition Hierarchy (Ancestors)

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Gilead Study Director

  Gilead Sciences

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 5, 2020
• First Posted: July 1, 2020
• Study Start: October 23, 2020
• Primary Completion: August 6, 2021
• Study Completion (Estimated): December 1, 2027
• Last Updated: February 2, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (17)